Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Jefferam1on Apr 03, 2017 3:41pm
125 Views
Post# 26069797

RE:RE:RE:Antibe Therapeutics grants options to purchase common shares

RE:RE:RE:Antibe Therapeutics grants options to purchase common sharesI was under the same impression, infact, their corporte presentation:
https://www.antibethera.com/wordpress/pdf/presentations/Antibe%20Investor%20Presentation%20-%20January%202017.pdf

Page 16
  Phase 2 dose ranging study: placebo-controlled study to validate effectiveness, explore lower doses and establish go-to-market dose Clinical results anticipated by Q3/17
Phase 2 upper GI safety study: endoscopically-ascertained ulceration versus comparator NSAID (naproxen) Clinical results anticipated by Q2/18

Interesting that it changed.

I agree it seems a little high how many options are given out. But then again, can you imagine how much more motivated you'd be to have as much success as possible if you held that many options. Money is a good motivator.  
Now if they gave cash bonus to their employees that I wouldn't agree with. I wish the options were more along the line of 10% at 0.20 and 10% at 0.25.... Basically putting some in the money but others far enough out to have added motivation.
Bullboard Posts